Exhibit 10.1


RESEARCH
AGREEMENT


This
RESEARCH AGREEMENT (this “Agreement”) is made effective as of January 29, 2007
(the “Effective Date”) by and between ArQule, Inc., a Delaware Corporation,
with its principal place of business at 19 Presidential Way, Woburn, MA 01801 (“ArQule”)
and Boston Biomedical, Inc., a Delaware corporation, with its principal place
of business at 333 Providence Highway, Norwood, MA 02062  (“BBI”).


W I T N E S S E T H:


WHEREAS, ArQule
desires that BBI perform certain research on its behalf related to ArQule’s
biopharmaceutical drug development programs and BBI is willing to perform such
research;


NOW, THEREFORE, in
consideration of the foregoing, the mutual covenants and undertakings contained
herein and other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the Parties, intending to be legally bound,
hereby agree as follows:


ARTICLE 1


DEFINITIONS


In addition to
other terms defined elsewhere in this Agreement, the following terms shall have
the following meanings when used herein (any term defined in the singular shall
have the same meaning when used in the plural and vice versa, unless stated
otherwise):


1.1                                 “Applicable
Laws and Regulations” means federal, state and local laws and regulations
to the extent the same are applicable to (i) performance of this Agreement, and
(ii) the facilities and operations of the Parties.


1.2                                 “ArQule
Intellectual Property” shall have the meaning stated in Section 4.1 hereof.


1.3                                 “ArQule
Representative” means Stephen A. Hill, the employee of ArQule designated as
ArQule’s scientific and technical representative for consultation and
communication with BBI and the Principal Investigator regarding the Research
Program, and any successor thereto, as indicated by written notice from ArQule
to BBI.


1.4                               “Background
Technology” means any and all Intellectual Property conceived or reduced to
practice in whole or in part, by ArQule, its employees, agents, contractors
and/or consultants or otherwise owned, licensed or controlled by ArQule as of
the Effective Date, including the patents and patent applications listed on
Appendix C.


1.5                                 “BBI
Technology” means any and all Intellectual Property conceived or reduced to
practice, in whole or in part, by BBI, its employees, agents, contractors
and/or consultants


[*] = CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.  CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
WITH RESPECT TO THE OMITTED PORTIONS. 
OMITTED TEXT IS INDICATED BY A “*”.













other than in performance of the Research Program, but excluding any
ArQule Intellectual Property.


1.6                                 “Intellectual
Property” means, collectively, all inventions, discoveries, materials
(including Proprietary Materials), data, formulae, databases, information,
know-how, processes, methods, specifications, works of authorship, and
designations of origin that now exist or later come into being.


1.7                                 “Intellectual
Property Rights” means all manner of U.S. and foreign legal protection of
rights in and to Intellectual property including patents and patent
applications and all reissues, reexaminations, renewals, extensions, divisions,
continuations and continuations-in-part of patents and patent applications,
trade secrets, property rights, copyrights, trademarks and servicemarks.


1.8                                 “Materials”
means any tangible biological, chemical, or physical materials.


1.9                                 “Party” means ArQule or BBI, and “Parties” means ArQule and BBI.


1.10                            “Person”
means a natural person, corporation, partnership, trust, joint venture,
governmental authority or other entity or organization.


1.11                           “Principal
Investigator” means Chiang J. Li, an employee of BBI, who shall have
primary responsibility for the performance of the Research Program, and any
successor thereto selected in accordance with Section 2.9.


1.12                           “Program
Intellectual Property” means all Intellectual Property (including Program
Materials, Program Records and enhancements of and improvements to Background
Technology) conceived, identified or reduced to practice in whole or in part by
either Party individually or by the Parties jointly in the performance of the
Research Program, but excluding any BBI Technology.


1.13                           “Program
Materials” means Materials that are discovered or developed in whole or in
part in the performance of the Research Program.


1.14                           “Program
Records” means scientific notes, notebooks and data arising from or
directly pertaining to the Research Program.


1.15                           “Proprietary
Materials” means confidential or proprietary Materials of ArQule which are
furnished by ArQule to BBI in connection with the performance of the Research
Program.


1.16                           “Research
Program” means the research described in Appendix A to this Agreement
relating to ArQule’s drug development programs including work relating to ARQ 171/ARQ
501 mechanistic equivalence; SiRNA rescue for E2F and E2F isoform elevation
specificity; mice study reports for studies that are relevant to E2F method of
action; and other drug combination studies both in vitro
and in vivo for ARQ 197.



 2
 









1.17                           “Senior
Director” means Dr. David Leggett, and  any successor thereto
designated by the Principal Investigator upon written notice to ArQule.


1.18                           “Term”
shall have the meaning stated in Section 6.1 hereof.


1.19                           “Third
Party” means any Person that is not a Party to this Agreement.


ARTICLE 2


RESEARCH PROGRAM
AND COMPENSATION


2.1                                 Conduct
of Research Program.  Commencing on
the Effective Date, BBI shall conduct the Research Program.  BBI shall carry out the Research Program
under the direction of the Principal Investigator in consultation with the
ArQule Representative with respect to the deliverables set forth in Appendix A
and in accordance with the terms set forth in Appendix A to this Agreement,
provided that the Principal Investigator shall have final authority with
respect to the scientific methodology utilized by BBI in performance of the
Research Program in accordance with the terms of this Agreement.


2.2                                 Dedicated
Personnel. BBI shall commit a total of  twenty-eight
(28) full-time equivalents (“FTEs”) dedicated solely to the performance of the
Research Program pursuant to this Agreement for the period from the Effective
Date through May 31, 2007 and twenty-three (23) such FTEs for the period from
June 1, 2007 to September 30, 2007.  For
purposes of this Agreement, an FTE is the equivalent of the full-time effort
(approximately 1700 work hours) of one qualified Person for a period of one
year.  The amount payable by ArQule for
an FTE on an annualized basis including associated overhead and support costs
is approximately *.


2.3                                 Funding
and Resources.  Subject to Sections 2.9 and 2.10 hereof,
ArQule shall pay BBI for performance of the Research Program during the term of
this Agreement in accordance with the payment schedule set forth in Appendix B
(the “Payment Schedule”).  ArQule shall
also provide research support as the Parties may mutually deem necessary in the
form of loaned equipment (the “Loaned Equipment”), Background Technology,
Proprietary Materials, and Confidential Information (as defined in Section
5.1).  Loaned Equipment shall include
bench-top laboratory and office equipment located at 333 Providence Highway,
Norwood, MA 02062 on the Effective Date, other equipment listed in Appendix C
and any additional laboratory or office equipment provided to BBI by ArQule
during the Term.  At the expiration or
earlier termination of this Agreement, and provided BBI shall not be in breach
hereof, the ArQule Representative and the Principal Investigator shall
negotiate in good faith an agreement on mutually acceptable terms for
disposition of Loaned Equipment, if any, that the ArQule Representative decides
is surplus to ArQule’s internal requirements (the “Disposition Agreement”),
including disposition by sale or lease to BBI of all or a portion thereof on
terms which reflect fair market value of the Loaned Equipment.  All Loaned Equipment which is not subject to
the Disposition Agreement shall be returned to ArQule upon the expiration or 



 3
 









earlier termination of this
Agreement.  Indicated on Appendix C are
items of equipment which the Parties currently expect will be surplus to ArQule’s
internal requirements at the expiration or earlier termination of this
Agreement; provided, however, that such indication shall not be binding upon
the Parties. For purposes of clarity, any equipment which is purchased by BBI
during the Term shall remain BBI’s property following termination or expiration
of this Agreement.


2.4                                 Limited
Use License.  Except as otherwise prohibited by the terms
of any agreement by virtue of which ArQule acquired rights in Background
Technology, ArQule hereby grants to BBI a non-exclusive, worldwide,
royalty-free license, coterminous with this Agreement, under ArQule’s rights to
Background Technology and/or Program Intellectual Property solely to perform
BBI’s obligations under this Agreement.                         ArQule and
BBI will cooperate to obtain the consent of any third party necessary to permit
BBI to use the Background Technology including  the licenses listed in
Appendix D.


2.5                                 Transitional
Services.  ArQule will provide
transitional services, including administrative, electronic security and
information technology services to BBI for up to thirty (30) days (or less if
requested by BBI and more if mutually agreed by the Parties) after the
Effective Date.  Such services will be
provided at a cost equal to the direct out-of-pocket cost to ArQule and the
amount thereof will be deducted from the next occurring Fixed Payment.


2.6                                 Third-party
Support; Research Support.  If deemed
necessary or advisable by mutual agreement of the Parties in connection with
the Research Program, ArQule shall continue to permit BBI to utilize during the
Term the services of commercial and institutional research facilities with
which it has service contracts prior to the Effective Date, and any new service
contracts entered into by ArQule during the Term, provided that, such
utilization shall be coordinated by, and undertaken only with the prior
approval of, the ArQule Representative and any incremental cost of such use
shall be borne by BBI.


2.7                                 Payments.  Subject to Sections 2.9 and 2.10 hereof,
ArQule shall make periodic payments in advance to BBI as set forth in the
Payment Schedule (each, a “Fixed Payment”) and contingent payments as set forth
in the Payment Schedule upon successful accomplishment of research goals and
production of deliverables as specified in the Research Plan (each, a “Performance
Payment”).  All payments shall be paid in
U.S. Dollars by check or electronic transfer, as set forth in the Payment
Schedule, or by such other method
mutually agreed upon by the Parties.


2.8                                 Principal
Investigator.  The Principal
Investigator shall devote such of his time and attention to his duties under
the Research Program as shall be reasonably necessary to the performance of the
Research Program; provided, however, that upon designation by Principal
Investigator, the Senior Director shall have full authority to communicate with
ArQule and to manage the day-to-day performance of the Research Program.  If the Principal Investigator terminates his
service with BBI or otherwise becomes unavailable to work on the Research
Program for any reason for a period of time which would, in the reasonable
judgment of ArQule, materially and adversely affect the performance of the
Research Agreement, BBI may conduct the Research Program through a replacement
Principal Investigator with comparable training and experience, provided
that:  (i) BBI shall promptly notify
ArQule of the termination or unavailability of the Principal Investigator; and
(ii) ArQule shall have the right to approve any 



 4
 









replacement Principal
Investigator proposed by BBI. 
Notwithstanding the foregoing, based on the work remaining to be
completed in connection with the Research Program and the expertise required to
complete such work, ArQule shall have the right to reject any proposed
replacement Principal Investigator and cause this Agreement to be terminated in
accordance with Section 6.3.


2.9                                 Offset;
Liability for Overpayment.  In the
event ArQule makes or becomes obligated to make any payment on behalf of BBI,
whether as a result of BBI’s failure to pay or due to contractual or employment
relationships existing as of the Effective Date, ArQule shall be entitled to a
credit for any such payment and may deduct the amount of such payment from any
subsequent Fixed or Performance Payment due from ArQule to BBI hereunder.  In the event BBI is unable for any reason to
provide the number of FTEs specified in Section 2.2, ArQule shall continue to
make the Fixed Payments; provided, however, that a portion of each such Fixed
Payment (the “Earmarked Amount”) shall be used solely for the acquisition of
third-party products and services in furtherance of the Research Program so as
to compensate for the reduction in the number of FTE’s working on the Research
Program or, if not so used, shall be refunded to ArQule.  The Earmarked Amount shall be equal to the
actual direct labor costs, fringe benefits and consumable expenses of BBI
personnel whose termination of employment or other unavailability cause the
number of FTEs engaged in the Research Program to fall below the number
specified in Section 2.2.   At the end of
each month during the Term, BBI will advise ArQule of unscheduled changes in
the number of FTEs involved in the Research Program so as to permit calculation
of Earmarked Amounts to be included in future Fixed Payments.  If ArQule is entitled to credits, deductions
or refunds under this Section which exceed the amounts payable by ArQule
hereunder, BBI shall be liable for and ArQule shall be entitled to collect the
amount of such excess from BBI.


2.10                           Reduction
in FTEs.  Notwithstanding any other
provision of this Agreement if, at any time during the Term, the number of FTEs
engaged in performance of the Research Agreement is fewer than sixteen (16),
the ArQule Representative and the Principal Investigator shall meet to discuss
the effect of such reduction in staffing on performance of this Agreement.  If the ArQule Representative concludes, or
the Principal Investigator informs him, that the Research Program cannot be
carried out in accordance with the terms of this Agreement, the Parties shall
attempt to agree upon amendments to the performance and payment terms
hereof.  If the Parties are unable to
agree, either Party, in addition to any other remedies available to it at law
or in equity, may terminate this Agreement.


ARTICLE 3


RECORDS, REPORTS
AND ACCESS


3.1                                 Agreement
Records. BBI shall keep and maintain during the
Term and for a period of three (3) years thereafter complete, accurate and
authentic (i) financial and business records, (ii) Program Records in
accordance with ArQule notebook policy and in a manner suitable for
establishing appropriate Intellectual Property Rights, and (iii) other records
regarding Intellectual Property suitable for establishing the respective
Intellectual Property Rights of the Parties therein.  The records referred to in clauses (i)-(iii)
directly pertaining to funding, staffing, performance or outsourcing of the
Research Program including laboratory notebooks of BBI (collectively, the “Agreement
Records”) shall, upon reasonable prior notice from the ArQule 



 5
 









Representative, be available for
inspection, auditing, and copying during regular business hours by ArQule
personnel designated by the ArQule Representative, subject to the
confidentiality provisions of Article 5 below.


3.2                                 Reports.


(a)  BBI shall produce
the reports specified as deliverables in Appendix A in a timely manner.  All reports and supporting data shall be
delivered in electronic format to the “E-Room” established by ArQule for that
purpose to which BBI shall be granted access.


(b)  In addition to such specified reports, BBI
shall, within thirty (30) days after the end of each calendar quarter during
the Research Program, provide the ArQule Representative with a written research
progress report containing a description, in summary format, of the research
and development work performed under this Agreement through the date of the
report and the results thereof if not otherwise covered under the specified
reports.  Such reports shall indicate the
specific duties and projects to which FTEs were assigned.


3.3                                 Access
and Communication.  If ArQule
identifies any reasonable scientific concerns with respect to BBI’s conduct of
the Research Program, the ArQule Representative and/or other ArQule employees
or representatives identified by the ArQule Representative may, as soon as
mutually convenient during regular business hours (but in no event more than
four (4) business days after notice to BBI) visit and inspect BBI’s facilities
utilized in the performance of the Research Program and examine, audit, and
copy the Agreement Records to determine compliance by BBI with the stated
objectives of the Research Program, BBI’s achievement of deliverables
thereunder, and relevant staffing and outsourcing issues, subject to the
confidentiality provisions of Article 5 below. 
The Principal Investigator or Senior Director and the ArQule
Representative shall communicate regarding performance of the Research Program
informally by telephone or electronic mail on a weekly basis or less frequently
upon mutual agreement.


ARTICLE 4


OWNERSHIP OF
INTELLECTUAL PROPERTY


4.1                                 Ownership.
ArQule shall solely and exclusively own all: (i) Intellectual Property
conceived or reduced to practice solely by or for ArQule by ArQule’s employees,
agents, contractors and/or consultants, excluding BBI, whether in connection
with the Research Program or otherwise; (ii) Proprietary Materials; (iii)
Background Technology; (iv) Program Intellectual Property; and (v) Intellectual
Property which constitutes an enhancement of or improvement to the Background
Technology or the Program Intellectual Property and which is conceived or
reduced to practice by BBI’s employees, agents, contractors and/or consultants
during the three (3) years following expiration or earlier termination of this
Agreement (clause (i) through (v), collectively, the “ArQule Intellectual
Property”).  BBI shall solely and
exclusively own all BBI Technology.



 6
 









4.2                                 Disclosure.  Any potentially significant ArQule
Intellectual Property shall be promptly disclosed by BBI in writing to the
ArQule Representative for ArQule’s evaluation. 
Such written disclosure shall contain sufficient scientific and
technical detail to convey a reasonable understanding of the nature, purpose
and characteristics of such Intellectual Property and form a basis, if
appropriate, for applying for, obtaining and perfecting Intellectual Property
Rights.


4.3                                 Assignments.


(a)   BBI shall cause its employees,
agents, contractors and consultants to assign to BBI their rights to any and
all ArQule Intellectual Property.


(b)  BBI shall assign, transfer and convey, and
hereby assigns, transfers and conveys to ArQule, all of its rights, title, and
interests in and to ArQule Intellectual Property.  Whenever requested to do so by ArQule, BBI
will execute any and all applications, assignments, or other instruments and
give testimony which ArQule shall deem necessary to apply for, obtain and
perfect its Intellectual Property Rights in and to such ArQule Intellectual
Property.  ArQule may utilize such ArQule
Intellectual Property to make, have made, use, sell, have sold, offer to sell,
and/or import any products or otherwise to practice any process for any lawful
purpose.  ArQule shall have no obligation
to account for or make any payments of any nature to BBI for its utilization of
such ArQule Intellectual Property and such enhancements and improvements other
than the Fixed and Performance Payments set forth in the Payment Schedule.


(e)  No Implied Licenses.  Except to the extent specifically and
expressly provided, nothing in this Agreement is intended to or shall be
interpreted as granting to a Party any license to or any rights, title or
interest in or under any Intellectual Property that is or that comes to be
owned by or licensed to the other Party, whether subordinate or dominant to any
other Intellectual Property.


ARTICLE 5


CONFIDENTIALITY;
PROPRIETARY MATERIALS


5.1                                 Confidential
Information.  Each Party (the “Receiving
Party”) shall keep, and cause its directors, officers, employees, advisers,
agents, contractors and sources of capital (“Representatives”) to keep strictly
confidential any information disclosed by the other Party (the “Disclosing
Party”) or otherwise made available to the Receiving Party concerning the
Research Program or otherwise concerning the business, operations, or
Intellectual Property of the Disclosing Party (whether in written media or
otherwise) (“Confidential Information”). 
“Confidential Information” shall not include information which the
Receiving Party can demonstrate by clear and convincing evidence:  (a) subsequently to the Effective Date
becomes generally available to the public other than as a result of disclosure
thereof by the Receiving Party; (b) subsequently to the Effective Date is
lawfully received by the Receiving Party on a nonconfidential basis from a
Third Party that is not itself under any obligation of confidentiality or
nondisclosure to the Disclosing Party or any other Person with respect to such
information; or (c) subsequently to the Effective Date is independently
developed by the Receiving Party 



 7
 









without use of or
reference to the Confidential Information of the Disclosing Party.  For avoidance of doubt and notwithstanding
anything to the contrary contained herein, all information concerning the
ArQule’s research and development programs or otherwise concerning its
business, operations, or Intellectual Property in the possession of, or
otherwise know to, BBI’s employees, agents, consultants or representatives as a
result of any employment or other relationship with ArQule on or prior to the
Effective Date and which is not exempted confidential treatment under the terms
of their agreements, if any, with ArQule shall be and remain Confidential
Information of ArQule and its exclusive property.


5.2                                 Nondisclosure.  The Receiving Party shall use Confidential
Information solely for the purposes of this Agreement and the transactions
contemplated hereby and may only disclose Confidential Information to those of
its Representatives whose duties reasonably require them to have access to such
Confidential Information, provided that such Representatives are bound by
agreements containing obligations of confidentiality and restrictions on use at
least as stringent as those contained in this Agreement.  Upon the expiration or termination of this
Agreement, or earlier at the request of the Disclosing Party, the Receiving
Party shall return to the Disclosing Party all originals, copies and summaries
of documents, materials and other tangible manifestations of Confidential
Information in the possession or control of the Receiving Party, except that
the Receiving Party may retain one copy of the Confidential Information in the
possession of its legal counsel solely for the purpose of monitoring its
obligations under this Agreement.  Each
Party shall be liable to the other for any disclosure of Confidential
Information by it or its Representatives not permitted by this Agreement.


5.3                                 Confidentiality
of Agreement.  Except as otherwise
set forth in this Agreement, each Party shall maintain the confidentiality of
all terms and conditions contained in this Agreement as well as the existence
of the Agreement itself and, without the prior consent of the other Party which
consent shall not be unreasonably withheld, delayed or conditioned, neither
Party shall make any press release or other public announcement disclosing this
Agreement, any of its terms and conditions or the identity of the other Party
or otherwise disclose the same to any Third Party (other than to its
Representatives whose duties require familiarity with this Agreement), except
for such disclosures (a) as may be required by Applicable Laws and Regulations,
in which case the Party making disclosure shall provide the other Party with
prompt advance notice of such disclosure so that the other Party has the
opportunity if it so desires to seek a protective order or other appropriate
remedy; (b) as are included in any registration statement, prospectus, offering
memorandum, periodic report or other document or filing required to comply with
relevant securities laws; or (c) which are restatements of previously approved
disclosures.


5.4                                 Proprietary
Materials.


(a)  BBI shall use the Proprietary Materials only
in compliance with all applicable Laws and Regulations.  BBI shall not use the Proprietary Materials
in any in vivo experiments on human subjects. 
BBI shall not transfer any Proprietary Materials to any Third Party
without the prior written consent of the BBI.



 8
 









(b)  Any Proprietary Materials that are furnished
to BBI pursuant to this Agreement are provided for experimental purposes and
may have hazardous properties.  ARQULE
MAKES NO WARRANTY, EXPRESS OR IMPLIED, OF MERCHANTABILITY OR FITNESS FOR A
PARTICULAR PURPOSE, OR THAT THE USE OF THE BACKGROUND TECHNOLOGY AND THE
PROPRIETARY MATERIALS WILL NOT INFRINGE ANY INTELLECTUAL PROPERTY RIGHTS OF A
THIRD PARTY, OR ANY OTHER WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, WITH
RESPECT TO THE PROPRIETARY MATERIALS AND THE BACKGROUND TECHNOLOGY.


(c)  Return. 
Upon the expiration or earlier termination of this Agreement, the
Recipient shall, as directed by ArQule, either destroy or return to ArQule any
unused Proprietary Materials.


5.6                                 Survival.  The confidentiality and nondisclosure
obligations of this Article 5 shall survive the expiration or earlier
termination of this Agreement and remain in effect for a period of seven (7)
years following the expiration or termination of this Agreement.


ARTICLE 6


TERM AND
TERMINATION


6.1                                 Term.  This Agreement shall remain in full force and
effect from the Effective Date through September 30, 2007 (the “Term”), unless
terminated sooner in accordance with Sections 6.2 or 6.3 below.


6.2                                 Rights
of Termination of Either Party.  In
the event that either Party commits a material breach of its obligations under
this Agreement and fails to cure that breach within thirty (30) days after
receiving written notice thereof or if more than thirty (30) days is reasonably
required, is not diligently undertaking remedial action, the other Party may
terminate this Agreement effective upon expiration of such thirty-day cure
period.


6.3                                 Special
Right of Termination.  In addition to
its right set forth in Section 6.2, ArQule may terminate this Agreement by
giving written notice of such termination to BBI if (a) the conditions for
termination arise as set forth in Section 2.8, but only upon thirty (30) days’
prior notice and then only if within such thirty (30) day period, BBI is unable
to identify a candidate with the training and experience reasonably necessary
to serve as the Principal Investigator of the Research Program; or (b) (i) BBI
shall admit in writing its inability to pay its debts generally or make a
general assignment for the benefit of creditors,  (ii) any proceeding shall be instituted by or
against BBI (which is not dismissed within sixty (60) days) seeking to
adjudicate it bankrupt or insolvent, or seeking liquidation, winding up,
reorganization, arrangement, adjustment, protection,  relief, 
or composition  of  BBI 
or  its  debts under 
any  law  relating 
to bankruptcy, insolvency or reorganization or relief of debtors, or
seeking the entry of an order for relief or the appointment of  a receiver, trustee, custodian or other
similar official for it or for substantially all of its property; or (iii) BBI
shall take any corporate action to 
authorize  any  of 
the  actions  set 
forth  in Section 6.3 (b).



 9
 









6.4                                 Effect
of Expiration or Termination.  Upon
expiration or termination of this Agreement:


(a)  the Research Program shall terminate
effective as of the expiration or termination date; and


(b)  unless the Parties have entered into a
separate agreement for disposition of the Loaned Equipment on mutually
acceptable terms, it shall be returned to ArQule upon the expiration or earlier
termination of this Agreement.


6.5                                 Survival.  Expiration or earlier termination of this
Agreement shall not affect the rights and obligations of the Parties accrued
prior to expiration or termination (or the remedies of the Parties otherwise
available at law or in equity in relation to such rights and obligations).  The following provisions shall survive
indefinitely if no shorter period is provided for in such provision: Sections
3.1, 3.2, 4.1, 4.2, 4.3(b), Article 5, Sections 6.4, 6.5 and 6.6, Article 7 and
Sections 9.2, 9.5 and 9.12.


6.6                                 Completion
of Work in Progress.  Notwithstanding
termination of this Agreement, Research Program, BBI and ArQule shall cooperate
to bring the Research Program to an orderly conclusion including completing as
much of the work in progress as is reasonably practicable and collecting,
summarizing and recording results and conclusions therefrom, and BBI shall be
compensated in accordance with Appendix B for work performed in accordance with
Appendix A and on a time and materials basis for any work performed in excess
of the work contemplated under Appendix A.


ARTICLE 7


INDEMNIFICATION


7.1                                 General
Indemnification. BBI shall, to the fullest extent permitted by law,
indemnify, defend and hold harmless ArQule and any parent, subsidiary or
sibling entity of ArQule and their respective shareholders, directors,
officers, employees, agents, contractors, successors and assigns (“Indemnified
Parties”) from and against any and all suits, actions, legal or administrative
proceedings, claims, liens, demands, damages, liabilities, losses, costs, fees,
penalties, fines and expenses (including attorneys’ fees and expenses and costs
of investigation, litigation and settlement) (“Damages”), directly or
indirectly arising out of or connected with (i) the actual or alleged
breach of BBI’s representations, warranties or covenants contained herein;
(ii) injury to or death of persons (including BBI’s employees) and damage
to or destruction of property caused by the actions or inaction of BBI’s
officers, employees, agents, contractors; or (iii) BBI’s disclosure to ArQule
(except for disclosure which has been approved by ArQule or as is otherwise
necessary under Section 4 of this Agreement) or infringement or
misappropriation in the conduct of the Research Program, of any Intellectual
Property of a third party, whether or intentional, willful, inadvertent or
otherwise except to the extent that those Damages have been caused by the gross
negligence or willful misconduct of such Indemnified Parties as determined by a
court of competent jurisdiction in a final and non-appealable decision or in a
binding settlement between the Parties. 
Indemnification shall not be the exclusive remedy 



 10
 









of ArQule for Damages but
shall, whenever possible, be cumulative, in addition to, and not in lieu of any
other remedies available at law or in equity.


ARTICLE 8


WARRANTIES OF BBI


8.1                                 BBI
Representations.  BBI represents and
warrants to ArQule that:


(a)  BBI is a duly organized and validly existing
corporation in good standing under the laws of the jurisdiction in which it is
organized and has all requisite corporate power and authority for the ownership
and operation of its properties and for the carrying on of its business as now
conducted and as now proposed to be conducted. 
BBI is duly licensed or qualified and in good standing as a foreign
corporation authorized to do business in Massachusetts and in each other
jurisdiction in which the nature of the business transacted by it or the
character of the properties owned or leased by it requires such licensing or
qualification, unless the failure to so qualify does not and will not have a
material and adverse effect on the business operations or financial condition
of BBI.


(b)  BBI has all necessary corporate power and has
taken all corporate action required to make this Agreement and any other
agreements and instruments executed in connection herewith the valid and
enforceable obligations of BBI.


(c)  All authorizations, consents, approvals,
licenses, permits, registrations or exemptions from filing with any
governmental department, commission, board, bureau, agency or instrumentality
necessary for the performance by BBI of its obligations under this Agreement
shall have been obtained prior to, and shall be effective as of, the Effective
Date, or shall be obtained promptly thereafter but in any event prior to BBI’s
conduct of the activities necessitating such governmental consents, approvals,
licenses, permits and registrations.  BBI
shall maintain in all material respects during the Term, all such governmental
consents, approvals, licenses, permits and registrations.


(d)  BBI has the full power and right to grant to
ArQule the rights granted under this Agreement, and has not granted and shall
not grant any rights to any Third Party that are inconsistent with the rights
granted to ArQule under this Agreement.


(e)  BBI will not use in connection with the
Research Program any funds, equipment, or similar resources received through
grants, awards, or contracts from any Third Party without the prior written
consent of ArQule.


(f)  The Research
Program shall be carried out in accordance with prevailing industry standards
in a timely manner by personnel of BBI with the requisite skills, expertise and
experience and with Applicable Laws and Regulations.  BBI will not disclose to ArQule (except for
disclosure which has been approved by ArQule or as is otherwise necessary under
Section 4 of this Agreement), or intentionally or willfully infringe or
misappropriate in the conduct of the Research Program, any Intellectual
Property of a third party.



 11
 









Upon
execution of this Agreement, BBI shall provide ArQule with an opinion of its
counsel, Wilmer Cutler Pickering Hale and Dorr LLP, in the form of Appendix E
hereto.


8.2                                 ArQule
Representations.  ArQule represents
and warrants to BBI that ArQule has all necessary corporate power and has taken
all corporate action required to make this Agreement and any other agreements
and instruments executed in connection herewith the valid and enforceable
obligations of ArQule.


ARTICLE 9


MISCELLANEOUS


9.1                                 Independent
Contractors.  Each of the Parties
shall be furnishing its services hereunder as an independent contractor.  This Agreement shall not create any
association, partnership or joint venture between the Parties or an
employer-employee relationship.  No
officer, employee, agent, servant, guarantor or fiduciary of either Party shall
be, or shall be deemed to be, the officer, employee, agent, servant, guarantor
or fiduciary of the other Party by virtue of this Agreement, and each Party
shall be solely and entirely responsible for its acts and the acts of its
officers, employees, agents, and servants. 
Neither Party shall have or represent itself as having authority to
create any obligation or duty in the name of or on behalf of the other
Party.  This Agreement is not intended to
benefit any Person other than the Parties hereto and no Third Party shall have
any right to enforce this Agreement or obtain any remedy for its breach.


9.2                                 Governing
Law.  This Agreement shall be
construed and interpreted under and in accordance with the laws of the
Commonwealth of Massachusetts without regard to its conflicts of laws
provisions.  All suits, claims or other
causes of action arising out of or relating to this Agreement shall be brought
in a state or federal court sitting in the Commonwealth of Massachusetts and
each Party hereby consents to the exclusive jurisdiction and venue of such
court in that event.  In any proceeding
arising out of or in connection with the terms of this Agreement, the
prevailing Party, in addition to any other remedies that may be awarded, shall
be entitled to recover from the other Party its reasonable attorneys’ fees and
expenses and costs of investigation, litigation and settlement.  No action taken or right exercised by a party
under this Agreement shall in any manner act as an election or limitation upon
its remedies and rights otherwise provided under this Agreement or at law or in
equity.


9.3                                 Insurance. 
ArQule and BBI shall each obtain and maintain during the Term insurance
with coverages and policy amounts commercially reasonable for their respective
businesses.  Upon request, each will
provide the other with evidence of such insurance.


9.4                                 Counterparts.  This Agreement may be executed in any number
of counterparts, each of which shall be deemed an original but all of which
shall constitute one and the same instrument. 
This Agreement may be executed by facsimile.


9.5                                 Notices.  In any case where any notice or other
communication is required or permitted to be given hereunder, such notice or
communication shall be in writing and sent by 



 12
 









overnight express or
registered or certified mail (with return receipt requested) and shall be sent
to the following address (or such other address as either Party may designate
from time to time in writing):


If to ArQule:


ArQule, Inc.


19 Presidential
Way


Woburn, MA 01801


Telephone: (781)
994-0300


Telefax: (781)
994-0587


Attention:  President and Chief Executive Officer


Copy to:  General Counsel


If to BBI:


Boston Biomedical,
Inc.  

333 Providence Highway


Norwood MA


Telephone:  (781) 278-0900


Telefax:  (781) 762-9863

Attention:  President and Chief Executive
Officer


Copy to:  Michael D. Bain


Hale and Dorr Venture
Group


Bay Colony Corporate
Center


1100 Winter Street


Waltham, MA 02451


Telephone: 
(781) 966-2027


9.6                                 Assignment;
Binding Effect.  This Agreement shall
not be assigned or delegated, in whole or in part, by either Party without the
prior written consent of the other Party which shall not be unreasonably
withheld, delayed or conditioned and any attempted assignment without such
consent shall be null and void. 
Notwithstanding the preceding sentence, either party may assign, without
the prior written consent of the other party, all (but not less than all) of
its rights and delegate all (but not less than all) of its obligations under
this Agreement to (i) any entity that is a purchaser or other successor in
interest to all or substantially all of the business or assets of such Party or
(ii) to an affiliate of such Party; provided, however, that notwithstanding any
such assignment and delegation to an affiliate, the assigning and delegating
party shall remain primarily, jointly and severally liable for the performance
by such affiliate of this Agreement. 
This Agreement shall be binding upon the successors and permitted
assigns of the Parties.



 13
 









9.7                                 Entire
Agreement.  This Agreement and the
Appendices hereto and (when executed) the proposed sublease of premises at 333
Providence Highway, Norwood MA by and between the Parties (the “Sublease”)
constitute related elements of a larger transaction and, as such, the entire
and complete understanding between the parties with respect to the covered
subject matter.  Such documents replace,
supersede and render void any and all predecessor agreements between the
parties, whether written or oral regarding such subject matter.  Neither Party has entered into this Agreement
in reliance upon any representation, warranty, covenant or undertaking of the
other Party that is not set forth or referred to in this Agreement or the
Sublease.


9.8                                 Amendment.  This Agreement may be varied, amended or
extended only by the written agreement of the Parties acting through their
respective duly authorized officers or representatives, specifically referring
to this Agreement.


9.9                                 Severability.  If any provision of this Agreement or the
application thereof is held by any court of competent jurisdiction to be
invalid, illegal or unenforceable, such invalidity shall not affect the other
provisions of this Agreement, the enforceability of this Agreement as a whole
or the enforceability of such provision in other jurisdictions to the extent
permitted by law.  In such event, the
Parties shall promptly negotiate in good faith a lawful, valid and enforceable
provision that is as similar to the invalid provision as may be possible.


9.10                           No
Waiver of Rights.  No waiver by any
party of any obligation under this Agreement, or of any breach thereof, shall
constitute a continuing or additional waiver of such obligation or breach or of
any other prior, contemporaneous or subsequent obligation or breach, whether of
the same, similar or different nature. 
No waiver of any obligation hereunder, or of any breach thereof, shall
be effective unless in writing and signed by a duly authorized officer or
representative for the Party giving the waiver.


9.11                           Force
Majeure.  A Party shall be excused
from performing its obligations under this Agreement if its performance is
delayed or prevented by any event beyond such Party’s reasonable control,
including, but not limited to, acts of God, fire, explosion, weather, disease,
war, insurrection, civil strife, riots, government action, or power failure;
provided that such performance shall be excused only to the extent of and
during such disability.  


9.12                     Headings and Interpretations.


(a)        The descriptive headings
contained in this Agreement are included for convenience of reference only and
shall not affect the meaning or interpretation of this Agreement.


(b)  Unless otherwise specified, all references to “days”
are to calendar rather than business days.


(c)  Wherever any provision of this Agreement uses
the term “including” (or “includes”), such term shall be deemed to mean “including
without limitation” and “including 



 14
 









but not limited to”
(or “includes without limitation” and “includes but is not limited to”)
regardless of whether the words “without limitation” or “but not limited to”
actually follow the term “including” (or “includes”).


(d)  The Appendices to this Agreement, and the
terms and conditions incorporated in the Appendices shall be deemed integral
parts of this Agreement and all references herein to this Agreement shall
encompass such Appendices and the incorporated terms and conditions.


(e)  Unless otherwise explicitly stated, in the
event of any conflict between the terms of the Agreement and the terms and
conditions of any of the Appendices hereto, the terms of the Agreement shall
prevail.


(g)  This Agreement shall be construed as if both
Parties drafted it jointly, and shall not be construed against either Party as
principal drafter.


9.13                           Further
Assurances.  On and after the Effective Date, the Parties shall
cooperate with respect to the taking of such actions, including execution and
delivery of documents, instruments and amendments as the Parties may deem
reasonably necessary to consummate the transactions contemplated hereby.


[The signature
page follows.]



 15
 









IN WITNESS
WHEREOF, the Parties hereto have caused this Agreement to be executed by their
duly authorized officers as of the date set forth above.


	
  ArQule, Inc.

  	
   

  	
  Boston Biomedical, Inc.

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  By:

  	
  /s/ Stephen A.
  Hill

  	
   

  	
   

  	
  By:

  	
  /s/ Chiang J. Li

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Name: 

  	
  Stephen A. Hill

  	
   

  	
  Name: 

  	
  Chiang J. Li

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title:

  	
  President and

  	
   

  	
  Title:

  	
  President and

  
	
   

  	
  Chief Executive Officer

  	
   

  	
   

  	
  Chief Executive Officer

  
										



 



 16














APPENDIX A


RESEARCH
PROGRAM


Scientific
Operational Deliverables


*


Project
specific scientific deliverables


ARQ 171/501


*


ARQ 197


*


Manuscripts
– Deliverables


·                  ARQ
501 * related studies submit to * (or equivalent) by *


·                  ARQ
171 & 501 (Second * paper) - * paper submitted to * (or equivalent) by  *, pending * approval


·                  197
*, submitted end of * to * (at least one high impact article – others can be
lower in impact) – (* or equivalent)


RESEARCH
PROGRAM DETAIL


	
  

  	
   

  	
  Realistic

  	
   

  	
  Critical

  	
   

  	
  Added

  Value

  Not

  Critical

  Path

  	
   

  	
  Comments About Deliverables

  
	
  

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  
	
  ARQ 501

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  
	
  

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  
	
  

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  
	
  ARQ 171

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  
	
  

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  
	
  

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  ARQ

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  



 











 


	
  197

  	
   

  	
  *

  	
   

  	
  *

  
	
   

  	
   

  	
  *

  	
   

  	
  *

  
	
   

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  
	
   

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  
	
   

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  
	
   

  	
   

  	
  *

  	
   

  	
  *

  
	
   

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  
	
   

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  
	
   

  	
   

  	
  *

  	
   

  	
  *

  
	
   

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  
	
   

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  
	
   

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  
	
   

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  
	
   

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  
	
   

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  
	
  ARQ 450RP

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  
	
  ARQ 800RP

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  	
   

  	
  *

  



 











APPENDIX
B


PAYMENT
SCHEDULE


Fixed Payments:


	
  ·

  	
   

  	
  Effective
  Date:

  	
   

  	
  $

  	
  *

  	
   

  
	
  ·

  	
   

  	
  February 1, 2007

  	
   

  	
  $

  	
  *

  	
   

  
	
  ·

  	
   

  	
  March 1, 2007

  	
   

  	
  $

  	
  *

  	
   

  
	
  ·

  	
   

  	
  April 1, 2007

  	
   

  	
  $

  	
  *

  	
   

  
	
  ·

  	
   

  	
  May 1, 2007

  	
   

  	
  $

  	
  *

  	
   

  
	
  ·

  	
   

  	
  June 1, 2007

  	
   

  	
  $

  	
  *

  	
   

  
	
  ·

  	
   

  	
  July 1, 2007

  	
   

  	
  $

  	
  *

  	
   

  
	
  ·

  	
   

  	
  August 1, 2007

  	
   

  	
  $

  	
  *

  	
   

  
	
  ·

  	
   

  	
  September 1, 2007

  	
   

  	
  $

  	
  *

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  SUBTOTAL: 

  	
   

  	
  $

  	
  4,265,615

  	
   

  



 


Performance Payments:


·                  Submission of paper regarding first comprehensive
description of ARQ 197 by * to JPET (or
equivalent):  $*


·                  Submission of paper on ARQ 501 mechanism of action
studies to Cancer Research (or equivalent) by *:  $ *


·                  Delivery of historical study reports to ArQule by *:  $*


·                  ARQ 171 & 501 (second mechanism of action paper)
- Pharmacology and mechanistic comparability paper submitted to Cancer Research
(or equivalent) by *, pending *
approval:  $*


·                  Delivery of
final report for concrete demonstration of ARQ 171, ARQ 501 mechanistic
equivalence by *: $*


 


	
  SUBTOTAL:

  	
   

  	
  $

  	
  700,000

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  TOTAL:

  	
   

  	
  $

  	
  4,965,615

  	
   

  



For purposes of clarity, to the
extent that any of the timelines set forth above are extended by mutual
agreement of the Parties, the Performance Payment payable upon achievement of a
particular milestone shall be payable to BBI upon achievement of such milestone
within the applicable extended timeline.


Wire Instructions:











Check Payment Instructions:















APPENDIX
C


RESOURCES FURNISHED BY ARQULE


Loaned Equipment:


	
  Asset

  	
   

  	
  Detail List

  	
   

  	
  Status

  	
   

  	
  Possible

  Surplus

  
	
  4033

  	
   

  	
  FACScalibur Flow Cytometer

  	
   

  	
  TBD

  	
   

  	
  Y

  
	
  4575

  	
   

  	
  Amersham Incell 1000 HCS unit

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4041

  	
   

  	
  AKTA Explorer FLPC

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4033

  	
   

  	
  ChemiImager 5500

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4231

  	
   

  	
  Twister II plate handler

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4391

  	
   

  	
  Lycor Odyssey infrared imaging system

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4031

  	
   

  	
  5 Model 2350 VWR CO2 incubators

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4166

  	
   

  	
  complete In vivo caging system

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4815

  	
   

  	
  Beckman Coulter LS 6500 Liquid scintillation counter

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4031

  	
   

  	
  Beckman Avanti J-20 High Speed Centrifuge

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4206

  	
   

  	
  2 VWR Open Transfer Stations

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4030

  	
   

  	
  Shimadzu UV -VIS Double Beam Spectrophotometer

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4032

  	
   

  	
  Beckman L880 Centrifuge

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4050

  	
   

  	
  Office Cubicles

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  Brightfield Microscope

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4634

  	
   

  	
  VETSCAN HMII HEMATOLOGY SYSTEM

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4754

  	
   

  	
  BECKMAN COULTER, SW-28 ROTOR

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4126

  	
   

  	
  Olympus Microscope with Pixellink camera

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4031

  	
   

  	
  2 Baker SterilGard Biosafety Cabinet Model SG-400
  (2)

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  Rainin Instruments - Pipetmen (various)

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4417

  	
   

  	
  2 Model 2350 VWR CO2 incubators

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4435

  	
   

  	
  Model 2350 VWR CO2 Incubator

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4696

  	
   

  	
  Locus Animal Data Management Software

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4032

  	
   

  	
  BIO-RAD 60-well 0.5ml GeneAmp PCR System 9700

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4031

  	
   

  	
  Market Forge Autoclave Sterilizer w/ temperature
  control and 29” stand

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4031

  	
   

  	
  2 Baker SterilGard Biosafety Cabinet Model SG-600

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4031

  	
   

  	
  3 Olympus CK2 Binocular Inverted Microscope

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4246

  	
   

  	
  Type 90 Ti ULTRACENTRIFUGE ROTOR

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4443

  	
   

  	
  ULTIMA -86 UPRIGHT FREEZER

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4614

  	
   

  	
  Amersham INCELL 1000 Software

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4127

  	
   

  	
  Lab table system

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4032

  	
   

  	
  REVCO - 80C Freezer

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4774

  	
   

  	
  Brinkman Autoclave

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4618

  	
   

  	
  ANIGARD II CLEAN BENCH ANIMAL TRANSFER STATION

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4515

  	
   

  	
  2-D Gel apparatus

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  Lab table system

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4032

  	
   

  	
  Xray Film Processor

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4408

  	
   

  	
  ALLEGRA X-22R CENTRIFUGE

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4033

  	
   

  	
  Beckman GPR Benchtop centrifuge

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4032

  	
   

  	
  Baker SG-400 BioSafety Cabinet

  	
   

  	
  BBI

  	
   

  	
  Y

  



 











 


	
  4186

  	
   

  	
  Rotary enviromental
  shaker

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4148

  	
   

  	
  Stratagen Robocycler
  PCR machine

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4032

  	
   

  	
  BIO-RAD Electrophoresis
  system

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4031

  	
   

  	
  Beckman GS-6R Benchtop
  centrifuge

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4418

  	
   

  	
  REVCO - 80C Freezer

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4032

  	
   

  	
  Baker SG-600 BioSafety
  Cabinet

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4031

  	
   

  	
  Savant Speed Vac
  w/vacuum pump

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4107

  	
   

  	
  Model 2350 VWR CO2
  Incubator

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4025

  	
   

  	
  4 office desk systems

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4407

  	
   

  	
  Beckman JA-10 rotor

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  Rotary Evaporator -
  Buchi

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4205

  	
   

  	
  PuriCare* Bedding
  Disposal Station, Labconco*

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4411

  	
   

  	
  Eppendorf Model 5417R
  (Refrigerated) Centrifuges

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4031

  	
   

  	
  Orbital Environ Shaker
  Model 3527, CSA 120V

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4031

  	
   

  	
  Baker SterilGard
  Biosafety Cabinet Model SG-400

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4030

  	
   

  	
  Molecular Devices
  Versamax Turntable Microplate Reader

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4031

  	
   

  	
  Beckman Refrigerated
  Benchtop Centrifuge model GPR

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4412

  	
   

  	
  ALLEGRA X-12R
  Centrifuge

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  Microscope

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4025

  	
   

  	
  7 Office desk systems

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4032

  	
   

  	
  Water Still

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4032

  	
   

  	
  Labconco Fume Hood
  model 2247300

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4032

  	
   

  	
  HydroTech Gel Dryer
  System w/ pump

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4031

  	
   

  	
  Beckman rotor model
  JA-20

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4034

  	
   

  	
  Fume Hood Installation

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  Eppendorf
  microcentrifuge

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4033

  	
   

  	
  Mettler Gram Balance

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4032

  	
   

  	
  Sonicator

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4031

  	
   

  	
  Beckman rotor model
  JA-14

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  Mini-Protean 3
  electrophoresis cell & trans-blot cell

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4030

  	
   

  	
  Fisher Waterjacketed
  CO2 Incubator

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4031

  	
   

  	
  Buchi rotary evaporator
  model R-114C

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  VWR Ependorf
  microcentrifuge Model 5415D

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  VWR Ependorf
  microcentrifuge Model 5415D

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4033

  	
   

  	
  Stratalinker

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  VWR Ependorf Centrifuge
  Model 5415C, Brinkman

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4032

  	
   

  	
  Various Pipets

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  Hydrogenation Apparatus
  500 mL

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  Bio-Rad Transblot
  System

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4031

  	
   

  	
  Mettler gram balance,
  model AB104

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4026

  	
   

  	
  Computer Laptop (Skip’s
  Dell System)

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4026

  	
   

  	
  Data Projector 800x600
  SVGA w/remote

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  Dreiding Stereomodels

  	
   

  	
  BBI

  	
   

  	
  Y

  



 











 


	
  4032

  	
   

  	
  Radioscope Monitors,
  Pancake Probe

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4026

  	
   

  	
  Computer Dell Optiplex
  GX240, Pentium IV(2)

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4033

  	
   

  	
  Lab Tables - Animal
  room

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  Lab Table with epoxy
  resin benchtop (3)

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4025

  	
   

  	
  Used Steelcase
  Workstations (3)

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  Rotary Evaporator
  -Buchi, R-3000

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4025

  	
   

  	
  Used Haworth
  Workstations (4)

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4025

  	
   

  	
  Global File Cabinets
  (3)

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4032

  	
   

  	
  Isolation System (2)

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4033

  	
   

  	
  Isolation systems (2)

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  2 Door Refrigerator -
  VWR Scientific

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4031

  	
   

  	
  Dry Bath Incubator (2)

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4032

  	
   

  	
  5-shelf Rack with
  casters (2)

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4032

  	
   

  	
  5-shelf Rack with
  casters (2)

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  Bio-RAD mini-protein 3
  system

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  Vacuum Pump 7.4 CFM MDL
  M12C - Fisher

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4026

  	
   

  	
  Computer ADS Pentium
  III 550

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4026

  	
   

  	
  Computer ADS Pentium
  III 550

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  Taylor Wharton LN2
  Dewar 35VHC

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4031

  	
   

  	
  Taylor Wharton LN2
  Dewar 35VHC

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  VWR Scientific
  Incubator - Model 2005

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4025

  	
   

  	
  4003 Arnot Black Leather
  Chairs (18)

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4026

  	
   

  	
  Dell Optiplex GX50 (3)
  w/17” monitors & MS Office Pro

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4033

  	
   

  	
  Work Tables (2)

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4026

  	
   

  	
  Computer Dell Latitude
  C610 Notebook

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4032

  	
   

  	
  Solvent Storage Cabinet

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4031

  	
   

  	
  Mettler gram balance,
  model PB1502

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  CEN-MED C-Max 100,
  Binocular Microscope

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4026

  	
   

  	
  Computer Dell Latitude
  Notebook

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  VWR benchtop
  centrifuge, model 340pH/mVc

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4031

  	
   

  	
  VWR Incubator, 2.6 CF

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  Hotpoint 18 cu.ft.
  refrigerator freezers (2)

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  VWR power supply
  apparatus 500V E-C

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4031

  	
   

  	
  Eppendorf Microfuge
  model 5415C w/ rotor

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4031

  	
   

  	
  Eppendorf Microfuge
  model 5415C w/ rotor

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4032

  	
   

  	
  Incubator Isotemp, 2.5
  cu ft model 625D

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4026

  	
   

  	
  Computer Dell Latitude
  C610 Notebook Pentium III

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4025

  	
   

  	
  Used Steelcase
  Workstations (2)

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4026

  	
   

  	
  Dell Optiplex GX50
  w/17” flat panel monitor

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4032

  	
   

  	
  Dissolved Oxygen Meter

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4026

  	
   

  	
  Dell Optiplex GX50 (3)

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4033

  	
   

  	
  Lab Chairs

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4026

  	
   

  	
  Printer - HP Laserjet
  2100tn/3200

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4026

  	
   

  	
  Printer - HP Laserjet
  2100tn/3200

  	
   

  	
  BBI

  	
   

  	
  Y

  



 











 


	
  4028 & 4029

  	
   

  	
  Fisher Lab Rotator

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4033

  	
   

  	
  GE Hotpoint
  Refrigerator/freezer 22 cu. Ft.

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  Glassware Cart

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4031

  	
   

  	
  Unitherm Hybridization
  Oven Model

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  Silver Recovery Floor
  Mount

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  Sanyo -30C Upright
  Freezer

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4030

  	
   

  	
  Scotsman Ice Maker

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4026

  	
   

  	
  Dell desktop Optiplex
  computers (2) w/monitors

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4026

  	
   

  	
  Dell Optiplex GX50
  desktop computers (3)

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  DNA Gel Box

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  Refrigerator/freezer 18
  cu. Ft.

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4032

  	
   

  	
  Hotplate/Stirrer (3)

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4033

  	
   

  	
  Orbital shaker

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4032

  	
   

  	
  Epoxy work surface

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4025

  	
   

  	
  8’ Oak Conference Table
  w/display board

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  Phenomenex analytical
  column

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4026

  	
   

  	
  Keurig coffee maker

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4030

  	
   

  	
  Heraeus Instruments
  Biofuge PICO

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  Power Pac

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  Lab Table with epoxy
  resin benchtop (1)

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4025

  	
   

  	
  Dining Tables (3) with
  15 chairs

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4032

  	
   

  	
  Mini Vortexer (3)

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4033

  	
   

  	
  Joule Box mini gel
  Electrophoresis system

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4033

  	
   

  	
  Fisher Mini-Vortexer

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4031

  	
   

  	
  VWR Orbital Shaker

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4030

  	
   

  	
  Precision Scientific
  280 Series Waterbath(2)

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4030

  	
   

  	
  Pipettes (6) with stand

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4030

  	
   

  	
  Corning PC 310
  Stirrer/Hotplate (2)

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4025

  	
   

  	
  Spets Hon Tiempo Iron
  Guest Chairs (6)

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4025

  	
   

  	
  Reception Chairs (4)

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  Fisher Labquake Tube
  Shaker

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  Fisher Labquake Tube
  Shaker

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  Fisher Scientific Optic
  Illuminator

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4026

  	
   

  	
  Shredder

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4025

  	
   

  	
  Bookcase (Chiang’s
  office)

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4030

  	
   

  	
  Beckman 310 PH Meter,
  12 PH/ISE Meter, & 34 PH Meter

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4025

  	
   

  	
  2-Drawer Lateral File Cabinet
  (2)

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  Fisher Colony Counting
  System

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4026

  	
   

  	
  Printer - HP Laserjet
  2200D

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  GE Undercounter
  Refrigerator

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4032

  	
   

  	
  Gesswein Sonicator

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4026

  	
   

  	
  Cyclis corporate
  graphics

  	
   

  	
  BBI

  	
   

  	
  Y

  



 











 


	
  4025

  	
   

  	
  4 Drawer Lateral File
  Cabinet

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4025

  	
   

  	
  4 Drawer Lateral File
  Cabinet

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4032

  	
   

  	
  Labquake Shaker, large
  with double deck tray

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  Beta Storage box

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4030

  	
   

  	
  Whirlpool
  refridgerator/freezer

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4026

  	
   

  	
  Whirlpool
  refridgerator/freezer

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  GE Undercounter Freezer

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  Dishwasher

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4025

  	
   

  	
  Spets Hon Tiempo Iron
  Guest Chair (3)

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4032

  	
   

  	
  Waterbath (2)

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4025

  	
   

  	
  Steelcase Guest Chairs
  (3)

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  Frigidaire 5 cu ft
  Freezer

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4030

  	
   

  	
  Kenmore
  Refrigerator/Freezer (2)

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4025

  	
   

  	
  8’ Racetrack Conference
  Table

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4025

  	
   

  	
  Global Task Lab Chairs

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4032

  	
   

  	
  Nylon cart cover (2)

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4026

  	
   

  	
  Dell 19” monitors (2)
  (Y. Li & X. Sun)

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4026

  	
   

  	
  Dell 17” monitors (3)

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4026

  	
   

  	
  Monitors (3)

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4025

  	
   

  	
  Reception Tables
  (Jordan’s)

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4030

  	
   

  	
  Precision Scientific
  185 Series Waterbath and VWR waterbath

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4025

  	
   

  	
  Oak Framed White Boards
  (4)

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4026

  	
   

  	
  Polycom Conference
  Phone Unit

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4026

  	
   

  	
  Polycom Conference
  Phone Unit

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4030

  	
   

  	
  Beckman #PHI40 PH Meter

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4025

  	
   

  	
  Supply Cabinet

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4026

  	
   

  	
  IBM Typewriter

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4025

  	
   

  	
  Trave Chrome Conference
  Table w/ glass top

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4028 & 4029

  	
   

  	
  GE Hotpoint
  Refrigerator/freezer 1.7 cu. Ft.

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4030

  	
   

  	
  IKA Labortechnik Ret
  Basic Temp Gauge

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4025

  	
   

  	
  Jesper 302S 36” Cherry
  Bookcase

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4030

  	
   

  	
  Precision #180
  Molecular Biology Water Bath

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4025

  	
   

  	
  Steelcase wheeled
  chairs (5)

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4030

  	
   

  	
  Bellco Glass Inc. hot
  shaker

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4026

  	
   

  	
  NEC monitor (B.
  Dahlberg)

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4025

  	
   

  	
  Haworth Pedestal File
  Cabinet

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4026

  	
   

  	
  Fireproof Safe

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4030

  	
   

  	
  GE microwave

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4026

  	
   

  	
  GE microwave

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4026

  	
   

  	
  Overhead Projector

  	
   

  	
  BBI

  	
   

  	
  Y

  
	
  4227

  	
   

  	
  4227-GENE PULSAR

  	
   

  	
  BBI

  	
   

  	
  Y

  



 











Background Technology:


	
  ARQULE

  #

  	
   

  	
  TITLE

  	
   

  	
  US PATENT

  NO.

  	
   

  	
  APPLICATION

  NO.

  
	
  AQ0101

  	
   

  	
  Treatment of Human Prostate Disease

  	
   

  	
  6,245,807

  	
   

  	
   

  
	
  AQ0102

  	
   

  	
  Method and Composition for Treatment of Cancer

  	
   

  	
  6,875,745

  6,664,288

  	
   

  	
   

  
	
  AQ0103

  	
   

  	
  Method of Treating Hematologic Tumors and Cancers

  	
   

  	
  7,070,797

  	
   

  	
   

  
	
  AQ0104

  	
   

  	
  Synthesis of Beta-Lapachone and its Intermediates

  	
   

  	
  6,458,974

  	
   

  	
   

  
	
  AQ0105

  	
   

  	
  Pharmaceutical Compositions containing Beta
  Lapachone, or Derivatives or Analogs Thereof, and Methods of Using Same

  	
   

  	
  6,962,944

  7,074,824

  	
   

  	
   

  
	
  AQ0106

  	
   

  	
  Novel Lapachone Compounds and Methods of Use Thereof

  	
   

  	
   

  	
   

  	
  10/528295

  
	
  AQ0107

  	
   

  	
  Novel Lapachone Compounds and Methods of Use Thereof

  	
   

  	
   

  	
   

  	
  10/810260

  
	
  AQ0108

  	
   

  	
  Method of Treating Cancers

  	
   

  	
   

  	
   

  	
  10/726467

  
	
  AQ0109

  	
   

  	
  Compositions for Modulation of SKP2 and Methods for
  Screening for Same

  	
   

  	
   

  	
   

  	
  10/793387

  
	
  AQ0110

  	
   

  	
  Use of Beta-Lapachone for Treating or Preventing
  Cancer

  	
   

  	
   

  	
   

  	
  10/846980

  
	
  AQ0111

  	
   

  	
  Compositions and Methods for Treatment of Cancer

  	
   

  	
   

  	
   

  	
  11/350,335

  
	
  AQ0112

  	
   

  	
  Compositions for Modulations of PARP and Methods for
  Screening for Same

  	
   

  	
   

  	
   

  	
  11/328993

  
	
  AQ0113

  	
   

  	
  Novel Lapachone Compounds and Methods for Use
  Thereof

  	
   

  	
   

  	
   

  	
  US2006/032660

  
	
  AQ0114

  	
   

  	
  Novel Lapachone Compounds and Methods for Use
  Thereof

  	
   

  	
   

  	
   

  	
  US06/20780

  
	
  AQ0115

  	
   

  	
  Methods and Compositions for Modulating CHK2 and
  Methods

  	
   

  	
   

  	
   

  	
  11/364609

  



 











 


	
  ARQULE

  #

  	
   

  	
  TITLE

  	
   

  	
  US PATENT

  NO.

  	
   

  	
  APPLICATION

  NO.

  
	
   

  	
   

  	
  for Screening for Same

  	
   

  	
   

  	
   

  	
   

  
	
  AQ0116

  	
   

  	
  Activated Checkpoint Therapy and Methods of Use
  Thereof

  	
   

  	
   

  	
   

  	
  10/622,854

  
	
  AQ0117

  	
   

  	
  Beta-Lapachone is a Broad Spectrum Anti-Cancer Agent

  	
   

  	
   

  	
   

  	
  11/060,746

  
	
  AQ0118

  	
   

  	
  Inhibitors of P38 and Methods of Using the Same

  	
   

  	
   

  	
   

  	
  10/556,161

  
	
  AQ0119

  	
   

  	
  Method of Treating Cancers

  	
   

  	
   

  	
   

  	
  11/062,875

  
	
  AQ0120

  	
   

  	
  Method of Treatment of Colon Cancer

  	
   

  	
   

  	
   

  	
  11/060,748

  
	
  AQ0121

  	
   

  	
  Method of Treatment of Lung Cancer

  	
   

  	
   

  	
   

  	
  11/068,459

  
	
  AQ0122

  	
   

  	
  Method of Treatment of Pancreatic Cancer

  	
   

  	
   

  	
   

  	
  11/060,747

  
	
  AQ0123

  	
   

  	
  Methods of Protecting Against Radiation Injury

  	
   

  	
   

  	
   

  	
  10/995,565

  
	
  AQ0124

  	
   

  	
  Quinone Prodrug Compositions and Methods of use

  	
   

  	
   

  	
   

  	
  11/201,170

  
	
  AQ0125

  	
   

  	
  Pharmaceutical Compositions of Beta-Lapachone and
  Beta-Lapachone Analogs with Improved Tumor Targeting Potential

  	
   

  	
   

  	
   

  	
  11/201,097

  
	
  AQ0126

  	
   

  	
  Synthesis of Imidazooxazole and Imidazothiazole
  Inhibitors of p38 Map Kinase

  	
   

  	
   

  	
   

  	
  US2005/037390

  
	
  AQ0127

  	
   

  	
  Treatment of Hematologic Tumors and Cancers with
  Beta-Lapachone, a Broad Spectrum Anti-Cancer Agent

  	
   

  	
   

  	
   

  	
  11/060,744

  
	
  AQ0128

  	
   

  	
  Inhibitors of P38 and Methods of Using the Same

  	
   

  	
   

  	
   

  	
  US2005/024441

  
	
  AQ0129

  	
   

  	
  RAF Inhibitors and Their Uses

  	
   

  	
   

  	
   

  	
  60/792,314

  
	
  AQ0130

  	
   

  	
  Novel Lapachone Compounds and Methods for Use
  Thereof

  	
   

  	
   

  	
   

  	
  60/808861

  60/839361

  



 











Proprietary Materials:  [TBD]











APPENDIX D


LICENSES REQUIRING CONSENT


1. Tet On License from IP Merchandisers  - Required
by BBI


2. InCell Corporation License Agreement for Cell Lines  - Required
by BBI


3. Brookhaven Science Associates, LLC License (March
2006) – [TBD]











APPENDIX E


FORM OF LEGAL OPINION